论文部分内容阅读
目的研究分析VTD方案(地塞米松、硼替佐米以及沙利度胺)对多发性骨髓瘤患者凝血功能的影响。方法多发性骨髓瘤患者62例作为研究对象,根据治疗方案的不同将患者分为对照组及研究组,每组31例,对照组采用常规药物进行治疗,研究组采用VTD方案进行治疗,并对两组患者的临床资料进行回顾性的总结分析,以探究VTD方案对多发性骨髓瘤患者凝血功能的影响。结果经治疗,研究组的总有效率为93.55%,明显高于对照组的总有效率80.65%,组间比较差异有统计学意义(P<0.05);研究组凝血功能的改善率为96.77%,显著高于对照组凝血功能的改善率83.87%,组间比较差异有统计学意义(P<0.05)。结论 VTD方案能够使多发性骨髓瘤患者凝血功能得到较好的改善,调节纤溶活性及抗凝,降低并发血栓发生的几率,是改善多发性骨髓瘤患者凝血功能的有效措施。
Objective To study the effects of VTD (dexamethasone, bortezomib and thalidomide) on the coagulation function in patients with multiple myeloma. Methods Sixty-two patients with multiple myeloma were enrolled in this study. According to the treatment plan, the patients were divided into control group and study group, with 31 cases in each group. The control group was treated with conventional drugs. The study group was treated with VTD program. The clinical data of two groups of patients were analyzed retrospectively to explore the effect of VTD program on the coagulation function in patients with multiple myeloma. Results After treatment, the total effective rate of the study group was 93.55%, significantly higher than that of the control group (80.65%), the difference between the two groups was statistically significant (P <0.05); the improvement rate of the coagulation function was 96.77% , Which was significantly higher than that of the control group (83.87%). The difference between the two groups was statistically significant (P <0.05). Conclusion VTD can improve the coagulation function of patients with multiple myeloma, regulate fibrinolytic activity and anticoagulation and reduce the risk of concurrent thrombosis, which is an effective measure to improve the coagulation function in patients with multiple myeloma.